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Abstract 
Background: Regenerative medicine is strictly dependent on stem cells as a source for a high diversity of somatic 
cells. However, the isolation of such from individuals suffering from severe genetic skin blistering diseases like epider‑
molysis bullosa (EB) is often associated with further organ damage.
Methods: Stem cells were isolated from 112 urine samples from 21 different healthy donors, as well as from 33 urine 
samples from 25 donors with EB. The cultivation of these cells was optimized by testing different media formulations 
and pre‑coating of culture vessels with collagen. The identity of cells was confirmed by testing marker expression, dif‑
ferentiation potential and immune‑modulatory properties.
Results: We provide here an optimized protocol for the reproducible isolation of mesenchymal stem cells from urine, 
even from small volumes as obtained from patients with EB. Furthermore, we offer a basic characterization of those 
urine‑derived stem cells (USCs) from healthy donors, as well as from patients with EB, and demonstrate their potential 
to differentiate into chondrocytes, osteoblasts and adipocytes, as well as their immune‑modulatory properties.
Conclusions: Thus, USCs provide a novel and non‑invasive source of stem cells, which might be applied for gene‑
therapeutic approaches to improve medical conditions of patients with EB.
Keywords: Urine‑derived stem cells (USCs), Epidermolysis bullosa (EB), Stem cell differentiation, Immune‑modulatory 
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Background
Epidermolysis bullosa (EB) is a devastating disease of 
the skin and mucous membranes, caused by mutations 
in either one of 17 genes encoding structural proteins 
required for skin integrity. Patients suffer from exten-
sive blistering upon minor mechanical impact due to the 
reduced connectivity of the skin layers. In severe sub-
types of EB, the continuous wounding of the skin causes 
a constant need for repair, which leads to the depletion 
of epidermal stem cells and thus to multiple chronic 
wounds [1].
Currently, ex vivo gene therapy is the most promising 
therapeutic approach concerning safety and technical 
realization. Mavilio et  al. [2] described the transplanta-
tion of in vitro engineered skin grafts (500 cm2 in total) 
onto the backside of the legs of a patient with EB. Epi-
dermal stem cells were isolated from patient skin biop-
sies, retrovirally transduced with a wildtype copy of the 
defective laminin β3 (LAMB3) cDNA in a MFG vector, 
and expanded in vitro. Clinically, the patient showed no 
more blistering in the area of the transplanted skin until 
6.5  years after the transplantation, proving the long-
term stability and safety of this approach [3]. However, 
the recovery of pertinent epidermal stem cells, which 
usually requires multiple skin biopsies, is an extremely 
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displeasing and painful demand especially for patients 
with EB. Thus, other sources for the non-invasive recov-
ery of stem cells, such as urine, are required.
Zhang and co-workers recently described the isola-
tion of mesenchymal-like stem cells from urine. These 
multi-potent cells are termed urine-derived stem cells 
(USCs) and were shown to have the potential to differ-
entiate towards osteocytes, chondrocytes, adipocytes, 
myocytes and endothelial cells [4–11]. Mesenchymal lin-
eages, such as fibroblasts, could be used for the treatment 
of patients suffering from dystrophic EB. Furthermore, 
recent reports suggest that mesenchymal stem cells can 
also be trans-differentiated into epidermal cells [12, 13] 
which might be beneficial for the treatment of the other 
subtypes. Thus, the isolation of USCs from urine might 
provide a non-invasive route for the painless recovery of 
stem cells from patients with EB.
We show here that by using an optimized protocol 
USCs can be reproducibly isolated from small volumes 
of urine from healthy donors, as well as from patients 
with EB. Recovered USCs were positive for various mes-
enchymal marker genes and could be differentiated into 
osteocytes, chondrocytes and adipocytes. Furthermore 
USCs showed similar immunomodulatory properties as 
amnion-derived mesenchymal stem cells.
Methods
Ethics
The isolation USCs from urine samples from healthy 
donors within this study was reviewed and approved by 
the ethic commission of the Medical University of Vienna 
(Ethik-Kommission der Medizinischen Universität Wien, 
Borschkegasse 8b/6, A-1190 Vienna, Austria).
For the isolation of USCs from patients with EB, the 
Salzburg ethics committee (Ethikkommission für das 
Bundesland Salzburg, Sebastian-Stief-Gasse 2, A-5020 
Salzburg, Austria) waived the formal review of this study 
by the ethics committee, since no clinical trials were 
conducted. This procedure is in accordance with the 
Krankenanstalten-und Kuranstaltengesetz, §8c (Austrian 
Federal Hospital Act, section 8c), and with the Salzburger 
Krankenanstaltengesetz 2000, §30 (Salzburg Hospital Act 
2000, section 30).
All the donors gave informed consent before providing 
urine samples. Thus, the study was performed in accord-
ance with the Declaration of Helsinki.
Isolation of USCs from urine
Mid- and last-stream urine from healthy donors was col-
lected into sterile recipes, transferred to 50 ml tubes and 
centrifuged for 5  min at 500×g. Thereafter, the super-
natant was discarded and cells were washed twice with 
PBS. The remaining pellet was re-suspended in culture 
medium and seeded into one well of a 24-well plate for 
male donors or a 6-well plate for female donors. Culture 
plates (Nunc) were either used without coating or coated 
with Collagen (Sigma Aldrich). Four different formula-
tions of culture medium were used:
1. Primary urine cells culture medium [pUSCs, accord-
ing to the method described by Zhang et al. [4], 50 % 
Keratinocyte-SFM (Gibco), 33.75  % DMEM (PAA), 
11.25 % Hams F12, 5 % Fetal calf serum (FCS, PAA), 
5  ng/ml Epidermal growth factor (Sigma Aldrich), 
50  ng/ml Bovine pituitary extract (Sigma Aldrich), 
30  ng/ml Cholera toxin (Sigma Aldrich), 0.4  μg/
ml Hydrocortisone (Sigma Aldrich), 5  ng/ml Insu-
lin (Sigma Aldrich), 1.8  ×  10−4 M Adenine (Sigma 
Aldrich), 5  μg/ml Holo-Transferrin (VWR), 2  nM 
Triiodo-L-thyronine (Life Technologies)].
2. MesenCult® MSC Basal Medium supplemented with 
MesenCult™ Mesenchymal Stem Cell Stimulatory 
Supplement (Stem Cell).
3. MesenPRO RS™ supplemented with MesenPRO RS™ 
Growth Supplement (Gibco).
4. EGM™-2 Bulletkit (Lonza).
All formulations were additionally supplemented with 
100 U/ml penicillin and 100 µg/ml streptomycin (Sigma).
Urine pH was measured and samples from healthy 
donors were also evaluated for the presence of glucose, 
leucocytes, nitrites, proteins and blood using Combur 
Test HC (Cobas) [14].
Immunophenotypic characterization of USCs 
by fluorescence microscopy
After three or four passages, USCs and adipose derived 
stem cells (ASCs) as control, were seeded into 8 well 
chamber slides (µ-Slide, IBIDI-Treat surface, IBIDI) 
without coating. Next day, cells were rinsed with PBS 
and fixed with 3.6 % formaldehyde in PBS for 10 min at 
room temperature. After two consecutive washes with 
PBS, the cells were stained for 1 h at room temperature 
with antibodies against CD14 (from mouse, ab7800, 
Abcam), CD34 (from mouse, FITC-labeled, 555821, BD 
Pharmingen), CD44 (from mouse, SAB4700184, Sigma 
Aldrich), CD73 (from mouse, FITC-labeled, 561254, BD 
Pharmingen), CD90 (from mouse, PE-labeled, 555596, 
BD Pharmingen), CD105 (from mouse, FITC-labeled, 
561443, BD Pharmingen), CD117 (from mouse, FITC-
labeled, 561443, BD Pharmingen), CD133 (from rabbit, 
ab19898, Abcam), Vimentin (from mouse, FITC-labeled, 
562338, BD Pharmingen), and Collagen I (from rab-
bit, ab292, Abcam). For antibodies without dye-conju-
gate, samples were washed three times and incubated 
with Dyelight488 or Dyelight549-conjugated secondary 
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antibodies against mouse or rabbit IgG (Jackson Immu-
noresearch) for 1 h. Finally, the wells were washed twice 
with PBS, stained with Hoechst 33258 for 5 min, washed 
once with PBS and analyzed by fluorescence microscopy 
on a Leica DMI-6000 microscope equipped with filter 
sets for DAPI, GFP and RFP.
Immunophenotypic characterization of USCs by flow 
cytometry
After three or four passages, USCs, as well as adipose 
derived stem cells (ASCs) and mesenchymal stem cells 
from umbilical cord [MSCs (UC)] as control, were har-
vested and fixed with 70  % Ethanol overnight at 4  °C. 
After two consecutive washes with PBS, the cells were 
stained for 1  h at room temperature with antibod-
ies against CD73 (from mouse, FITC-labeled, 561254, 
BD Pharmingen) and CD90 (from mouse, PE-labeled, 
555596, BD Pharmingen). Cells were washed thrice in 
PBS and analyzed on a Gallios Flow Cytometer (Backman 
Coulter).
Cell differentiation
For osteogenic differentiation, 3000 cells were seeded 
into one well of a 24-well plate without coating contain-
ing 1 ml DMEM low glucose (PAA) supplemented with 
10 % FCS, 10 nM dexamethasone (Sigma), 150 μM ascor-
bate 2-phosphate (Sigma), 10  nM vitamin D3 (Sigma) 
and 10  mM l-glycerophosphate (Sigma). The plates 
(Nunc) were kept in a humidified incubator (37  °C and 
5 % CO2) and the culture medium was changed twice a 
week for 28 days.
For healthy donors, the medium was aspirated after 
this time and the cells were washed three times with PBS. 
Then, cells were fixed in ice-cold 70 % ethanol for 1 h at 
−20  °C and washed three times with distillated water. 
The cells were incubated with 40 mM Alizarin Red solu-
tion (Sigma) at room temperature for 10 min and washed 
until all remaining traces of dye were removed. Repre-
sentative pictures were acquired on a Leica DMI micro-
scope equipped with a color-camera.
Cells differentiated from patients with EB were equili-
brated in an alkaline-phosphatase (AP)-buffer (0.1  M 
Tris–HCl pH 9.5, 0.1 M NaCl, 0.05 M MgCl2) for 10 min. 
Then, cells were incubated in 2 % NBT/BCIP (Sigma) in 
AP-buffer for 75 min and representative microscope pic-
tures were acquired.
For chondrogenic differentiation, 3000 cells were 
seeded in 24-well plates (Nunc) without coating con-
taining 2 ml DMEM/Ham’s F12 supplemented with 10 % 
FCS, 6  μg/ml insulin (Sigma), 0.2  mM ascorbic acid-2P 
(Fluka) and 10 ng/ml TGF-β1 (R&D). The plates (Nunc) 
were kept in a humidified incubator (37 °C and 5 % CO2) 
and the culture medium was changed twice a week for 
28 days.
After this period, the medium was aspirated and the 
cells were washed three times with PBS. Then, the cells 
were incubated with 3.6 % formaldehyde in PBS for 1 h, 
washed three times with distillated water and incubated 
with 1  % Alcian blue 8GX staining solution (Sigma) at 
room temperature for 30  min. The cells were washed 
until all traces of remaining dye were removed and repre-
sentative microscope pictures were acquired.
For adipogenic differentiation 14,000 USCs or ASCs as 
positive control were seeded into single wells of 6-well 
plates in growth medium (DMEM) for 2  days prior to 
adipogenic induction. Adipogenesis was induced by 
replacing the growth medium with fresh DMEM sup-
plemented with 549  µM 3-isobutyl-1-methylxanthine 
(Sigma), 1 µM Dexamethasone (Sigma), 549 µM hydro-
cortisone (Sigma) and 66  µM Indomethacin (Sigma). 
Medium was exchanged twice a week until day 24, fol-
lowed by Oil Red O staining. Differentiation medium 
was removed and cells were washed briefly with PBS 
twice and fixed by incubation in 3.6  % formaldehyde 
in PBS for 1  h at room temperature. Cells were then 
washed twice for 5  min each with PBS and incubated 
with 70 % ethanol for 2 min, followed by 10 min incuba-
tion in Oil red O working solution (1.8 mg/ml, Sigma). 
Cells were washed with PBS until all visible traces of 
remaining dye were removed and representative images 
were acquired.
Cell differentiations were confirmed by analyzing rela-
tive expression levels of different marker genes. Primer 
sequences are depicted below. Therefore, cells were 
harvested by trypsinization and total RNA was isolated 
using QIAzol Lysis Reagent (Qiagen), according to the 
manufacture’s protocol. RNA pellets were dried and re-
suspended in 50  μl RNase-free water. RNA was quanti-
fied using a NanoDrop Spectrophotometer (Thermo 
Scientific) and 100  ng of total RNA were reverse tran-
scribed using Dynamo cDNA synthesis kit (Finnzymes). 
For quantification of osteocalcin mRNA from healthy 
donors, qPCR was performed on a Rotorgene Q (Qiagen) 
using SensiMix Plus SYBR-Green Mix. Expression values 
were normalized to GAPDH and are indicated as fold 
changes relative to control.
The relative abundance of Collagen X, Aggrecan and 
GAPDH mRNAs were evaluated by semi-quantitive 
real-time PCR (SQRT-PCR). After reverse transcription 
as above, PCR products were generated using GoTAQ 
Polymerase (Promega) and separated on a 2 % agarose gel 
in 1× TBE buffer. PCR conditions were adjusted so that 
products were not in saturation.
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Target Primer sense Primer antisense
GAPDHa,b GCCAACGTGTCAGT 
GGTGGA
CACCACCCTGTTGCTG‑
TAGCC
Osteocalcina ATCAAAGAGGAGG 
GGAACCTA
AGGAAGTAGGGTGC‑
CATAACA
Osteocalcinb GTGCAGAGTCCAGC 
AAAGGT
TCAGCCAACTCGTCA‑
CAGTC
Collagen Xa CCCTTTTTGCTGCTA 
GTATCC
CTGTTGTCCAGGTTTTC‑
CTGGCA
Aggrecanb ACAGCTGGGGACAT 
TAGTGG
GTGGAATGCAGAGGTG‑
GTTT
a Primer used for USCs from healthy donors
b Primer used for USCs from patients with EB
Evaluation of immunomodulatory properties
The isolation of peripheral blood mononuclear cells 
(PBMCs) from whole blood and subsequent lympho-
cyte separation by plate adherence were performed as 
described previously [15]. Two different concentrations 
of USCs (4 ×  105 or 2 ×  105) were seeded and allowed 
to attach in individual wells of 6 well-plates (Nunc). Then 
the medium was replaced with 4 ×  105 lymphocytes in 
RPMI medium supplemented with 10 % FCS and 4 mM 
glutamine. For the activation of lymphocytes 2.4  μg/ml 
phytohemagglutinin (PHA, Sigma) were used. After 48 h, 
proliferation of lymphocytes was determined by bromo-
deoxyuridine (BrdU) incorporation as described previ-
ously [16]. Briefly, 10 μM BrdU were added to the culture 
medium and lymphocytes were harvested after 24  h. 
Fixation and permeabilization were followed by staining 
with anti-BrdU primary antibody (BD Biosciences) and 
goat-anti-mouse DyLight 488 conjugate secondary anti-
body (Pierce). Finally, BrdU incorporation was analyzed 
by flow cytometry (FACSDiva, BD Biosciences).
Statistical analysis
All the experiments were performed in biological tripli-
cates at least. Correlations were studied using the Pear-
son test. Association between urine volume and the 
presence of colonies was determined by Chi Square test. 
The differences in gene expression, as well as in the num-
ber of colonies depending on collagen coating were ana-
lyzed by Student’s t test. The statistical significance of cell 
culture characteristics depending on culture medium 
and lymphocytes proliferation were assessed by one-way 
ANOVA followed by Bonferroni multiple-comparison 
post hoc test. All statistical tests were performed in SPSS 
(IBM). p values ≤0.05 were considered significant.
Results
Characteristics of donors and urine
In order to establish a robust isolation protocol of USCs 
in our lab, we obtained in total 112 urine samples from 
21 different healthy donors. Only one sample was posi-
tive for nitrites, being all of them negative for the pres-
ence of glucose, leucocytes, proteins and blood. The 
volume of urine varied from 50 to 495  ml and the pH 
from 5.3 to 7.6, however these parameters did not cor-
relate with the presence or quantity of colonies of USCs 
(p = 0.484 and p = 0.58, respectively, Pearson Correla-
tion) (Additional file 1:  Table S1). These results indicate 
that neither pH, nor the volume of urine influence the 
success rate of USCs isolation. Even from small volumes 
of urine, as usually provided by patients with EB, USCs 
could be isolated.
Establishment of a reproducible USCs isolation protocol 
from healthy donors
In order to isolate USCs, urine was centrifuged and cells 
were seeded in pUSCs medium either in 24-well plates 
for male donors or 6-well plates for female donors. 
Urine samples showed a variable content of squamous 
cells, being in general more abundant in female sam-
ples (Fig.  1a). Cell colonies appeared most frequently 
between 3 and 8  days after isolation. Eventually, sam-
ples from specific donors showed the first colony after 
2–3 weeks.
In the following we define successful isolation of USCs, 
when at least one colony was obtained. As shown in 
Additional file 1: Table S1, the success rate of isolations 
from male donors was higher than from female donors 
(70 vs. 42  %). However, we observed that by isolating 
multiple samples from the same donor within 2  weeks 
(2–3 samples per day, 3 times per week), at least two 
successful isolations from each donor could be obtained 
independent of the donor’s sex.
Morphology of freshly isolated USCs‑enriched cells 
from urine
Urine derived cells exhibited morphologies ranging from 
more epithelial to more elongated-fibroblastoid, inde-
pendent of the donor. This indicates that a mixed popula-
tion of different cell types was present immediately after 
isolation. Representative pictures of primary colonies are 
shown in Fig.  1b. However, after three passages the cell 
morphology became homogeneously elongated-fibro-
blastoid in most of the isolations. This cell population 
homogeneous in morphology is henceforth referred to as 
USCs and was used for all upcoming experiments. It is 
unclear, however, if the epithelial cells are lost over pas-
saging due to the media enriching for fibroblastoid cells. 
The isolated cells reached confluence at around 12 days 
(Fig. 1c). In general the replicative life span ranged from 
4.5 to 12 population doublings following the first passage, 
after which cells stopped growing and displayed typical 
senescent morphology (Fig. 1d).
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Optimization of culture conditions
In order to optimize the culture conditions for USCs, we 
tested different media formulations. Consequently, urine 
samples were obtained from four donors and the cells 
were cultivated either in MesenCult, MesenPRO, EGM-2 
or pUSCs medium. We did not see major differences 
in cell morphology depending on the culture medium 
used, although cells grown in EGM-2 tended to display 
a more epithelial phenotype than with the other formu-
lations (Fig. 2a). Cells from only one out of five samples 
showed cell proliferation in EGM-2 and also in this case 
cells stopped growing after passage 3. Interestingly, when 
either MesenCult or MesenPRO medium was used some 
colonies appeared already as soon as 3  days after isola-
tion. Nevertheless, we did not find significant differences 
between the four media formulations regarding the nec-
essary timeframe for colony formation. The number of 
colonies and the time needed to passage the cells for the 
first time did not differ significantly either (Additional 
file 1: Table S2). Cells cultivated in MesenPRO or Mesen-
Cult stopped cell division after passage 1 in some cases, 
while in pUSCs medium they grew for longer periods 
of time and reached significantly more population dou-
blings (PDs) compared to MesenCult (p = 0.013) or Mes-
enPRO (p = 0.006) (Additional file 1:  Table S2).
In addition, we tested whether the pre-coating of 
culture dishes with collagen improved the efficiency of 
isolation and culture of USCs. As expected, the num-
ber of colonies was significantly higher when the plates 
were not coated (p = 0.026) (Fig. 2b), since adherence 
to plastic surfaces is typical for mesenchymal stem cells 
[14].
In summary these results indicate that USCs can be 
cultivated in different media formulations, but pUSCs 
medium without collagen coating of culture dishes is 
most efficient for expanding the cells.
Fig. 1 Morphology of USCs. a Immediately after seeding (d0), urine samples show different contents of squamous cells, ranging from only few cells 
to complete coverage of the surface (from left to right panel). Representative pictures of four different donors are shown. b Approximately 3 days 
after seeding, the formation of colonies could be observed. The variability in size and morphology between donors, as well as between two sam‑
ples from the same donor are shown. c Approximately 10 days (d10) after seeding, the cells reached confluence. Even within two different samples 
from the same donor, differences in cell morphology could be observed at his stage. d After ten PDs on average USCs stopped proliferation and 
showed the typical senescent morphology. Samples from two different donors are depicted
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USCs express typical markers for mesenchymal stem cells 
(MSCs)
In order to test if the urine-derived cells are indeed 
enriched for USCs, the expression of MSC surface mark-
ers including CD73, CD90 and CD105 [17], as well as a 
lack of hematopoietic surface markers was analyzed by 
indirect immunofluorescence. Adipose derived mes-
enchymal stem cells (ASCs) served as positive control. 
Indeed, the surface marker profile of USCs resembled 
closely that of ASCs, as both were positive for the mes-
enchymal stem cells markers CD44, CD73, CD90, 
CD105, Vimentin and Collagen I, and negative for the 
hematopoietic markers CD14, CD34, CD117 and CD133 
(Fig. 3a). Analysis of CD73 and CD90 by flow cytometry 
confirmed the homogenous expression of mesenchymal 
marker genes within the whole cell population (Fig. 3b).
These findings, together with the fact that USCs 
adhere to plastic surfaces are consistent with previous 
reports [6, 17] and corroborate that USCs closely resem-
ble MSCs.
USCs have the potential to differentiate into osteogenic, 
chondrogenic and adipogenic lineages
In order to further confirm that our USCs are function-
ally similar to MSCs and previously published USCs, we 
studied their potential to differentiate into osteoblasts, 
chondrocytes and adipocytes. Therefore, USCs were 
exposed to osteogenic induction medium for 4  weeks. 
At the end of this time period the cells aggregated and 
formed calcium precipitates, which were confirmed by 
alizarin red staining (Fig.  4a). On transcriptional level, 
osteocalcin mRNA expression showed a significant 
Fig. 2 Media optimization for the isolation and cultivation of USCs. a Comparison of the effect of different media formulations on the isolation and 
growth characteristics of USCs. The values represent the mean of at least biological triplicates, except EGM‑2, since only one sample showed prolif‑
eration in EGM‑2. Error bars represent the standard deviation. b Representative images of cells on day 6–7 after isolation of one donor. c Collagen‑
coating reduces significantly the efficiency of USCs‑isolation (p = 0.026). Error bars indicate the standard deviation of biological triplicates
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twofold increase in induced cells when they were com-
pared to an uninduced control (p = 0.05) (Fig. 4b).
When USCs were cultivated with chondrogenic induction 
medium over a period of 28 days, cells formed aggregates 
as expected during differentiation, and stained positive for 
proteoglycans using Alcian blue (Fig.  4c). At mRNA level, 
differentiated USCs exhibited detectable levels of Collagen 
X in contrast to the non-differentiated control cells (Fig. 4d).
Fig. 3 USCs surface marker expression patterns resemble those of ASCs. a Representative immunofluorescence images of USCs and ASCs as con‑
trol are shown. USCs, as well as ASCs, stained positive for the typical MSC markers CD44, CD73, CD90 and CD105, and negative for the hematopoi‑
etic markers CD14, CD34, CD117 and CD133. Additionally, the mesenchymal markers Vimentin and Collagen I stained positive both in USCs and 
ASCs. b Representative flow cytometry histograms of USCs stained for CD73 and CD90 reveal a single homogenous population of cells expressing 
both mesenchymal markers. Two replicates from other donors showed similar results
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Fig. 4 USCs have the potential to differentiate towards osteocytes, chondrocytes and adipocytes. a Osteogenic differentiation: After 28 days of 
culture in the induction medium, USCs stained positive for Alizarin red in contrast to the un‑induced control. Representative images are shown. b 
mRNA expression of Osteocalcin relative to GAPDH was analyzed by qPCR. Induced cells showed a significant increase compared to the un‑induced 
control (p = 0.05). Error bars indicate the standard deviation from three biological replicates (three different donors). Con. control, Ind. induced. c 
Chondrogenic differentiation: representative pictures showing morphological changes and alcian blue positive staining of USCs after 28 days of 
induction, compared to an un‑induced control, are depicted. d The chondrogenic marker Collagen X (Coll. X) could only be detected in induced 
cultures by semi‑quantitive PCR. GAPDH was used as loading control. Numbers represent different donors, I induced, C control, L 100 bp ladder. 
All bands are at the expected heights. e Adipogenic differentiation: USCs and ASCs were subjected to adipogenic differentiation for 24 days. Unin‑
duced cells served as control. The formation of lipid droplets was visualized by Oil Red O staining. Representative images are shown
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For adipogenic differentiation, USCs and ASCs as con-
trol were incubated for 24 days in adipogenic induction 
medium and stained with Oil Red O. Indeed, lipid drop-
lets were detected in USCs compared to the uninduced 
control, although they were smaller and appeared much 
later during the course of differentiation than in ASCs 
(Fig. 4e). The reason might be that ASCs are derived from 
adipose tissue and are thereby already pre-conditioned to 
efficiently differentiate towards adipocytes.
These results demonstrate that USCs are indeed able to 
differentiate towards the osteogenic, chondrogenic and 
adipogenic lineages.
USCs have immunomodulatory properties
Finally, we wanted to test if USCs also display the typi-
cal immunosuppressive activity towards lymphocytes, 
which was to our knowledge not done before. Therefore, 
USCs were co-cultured with lymphocytes and after PHA 
stimulation the proliferation levels of lymphocytes were 
analyzed by measuring BrdU incorporation. Indeed, 
USCs inhibited the formation of cell clusters typi-
cally found after in  vitro activation of lymphocytes [18] 
(Fig. 5a). Similarly, lymphocyte proliferation was signifi-
cantly reduced by 50  % (p =  0.02) by co-culturing with 
USCs at a lymphocytes:USCs ratio of 1:1 (Fig. 5b).
These observations strongly suggest that USCs display 
typical characteristics of MSCs, including surface marker 
profile, differentiation potential as well as immunomodu-
latory properties.
USCs from patients with EB
After the optimization of USCs isolation and culti-
vation, as well as the characterization of USCs from 
healthy donors, we tested if our protocol was also 
applicable to samples from patients with epidermoly-
sis bullosa in another laboratory (Fig. 6a). In total, 33 
urine samples were obtained from 25 donors, suffering 
from different types of EB (dystrophic EB, junctional 
Fig. 5 USCs display immunomodulatory properties. a The presence of USCs inhibited the typical cluster formation of lymphocytes after their 
activation by PHA. Representative pictures of lymphocytes alone (1:0) and lymphocytes and USCs at a 1:1 ratio are shown. b USCs reduced PHA‑
activated lymphocyte proliferation in a dose‑dependent manner. Error bars indicate the standard deviation of biological triplicates
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EB, EB simplex) (Additional file  1: Table S3). In con-
trast to urine samples from healthy volunteers, the 
average volume from patients with EB was only 
58.3 ml, probably due to the fact that in some patients 
the urinary tract is also affected from blistering and 
scarring, rendering urination painful. Interestingly, 
the mean number of colonies was with 1.6 colonies per 
patient only slightly lower than the mean number of 
healthy volunteers (1.9). The number of samples show-
ing cell proliferation was similar between both groups 
(60 % patients with EB, 58 % healthy volunteers) (Addi-
tional file 1: Table S3).
Fig. 6 Isolation and differentiation of USCs from patients with EB. a Representative colonies of USCs isolated from patients with EB are shown. b 
Chondrogenic differentiation: representative pictures showing morphological changes and alcian blue positive staining of USCs after 18 days of 
induction, compared to an un‑induced control, are depicted (left). The chondrogenic marker Aggrecan could only be detected in induced cultures 
by semi‑quantitive PCR. GAPDH was used as loading control. I induced, C control (right). c Osteogenic differentiation: after 15 days of culture in the 
induction medium, EB‑USCs stained positive for NBT/BCIP in contrast to the un‑induced control. Representative images are shown (left). mRNA 
expression of Osteocalcin (Osteoc.) was analyzed by semi‑quantitive PCR. Induced cells showed a significant increase compared to the un‑induced 
control. GAPDH was used as loading control. C control, I induced (right)
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Also EB-patient derived USCs differentiated into chon-
drogenic and osteogenic lineages, as could be shown by 
positive alzian blue (chondrogenic lineages) or NBT/
BCIP (osteogenic lineages) staining and morphologic 
characteristics of the respective lineages. Semi-qRT-PCR 
revealed the expression of lineage-specific genes com-
pared to undifferentiated controls (Fig. 6b, c).
These data confirm that our optimized protocol is also 
applicable to the reproducible isolation of functional 
USCs from urine of patients with EB.
Discussion
We describe here the isolation and characterization 
of cells from human urine termed USCs, which display 
similar markers, differentiation potential, adherence to 
plastic surfaces and immunomodulatory properties as 
adipose tissue derived mesenchymal stem cells (ASCs).
In contrast to the isolation of bulk urine cells and their 
reprogramming to induced pluripotent stem cells (iPSCs) 
recently described by us [19, 20], the direct isolation of 
USCs and their subsequent (trans-)differentiation in 
various cell lineages offers the advantage that transfec-
tion steps or the transduction with putatively oncogenic 
viruses can be completely omitted. However, since USCs 
have only a narrow differentiation potential compared to 
iPSCs, their usage for the generation of certain tissues, 
especially those originating from the ecto- and endo-
derm, is limited.
We and others already showed that USCs can be dif-
ferentiated into the main mesenchymal lineages, such as 
chondrocytes, adipocytes and osteoblasts. Already fibro-
blasts could be beneficial for the treatment of patients suf-
fering from dystrophic EB as a stable cell source for gene 
correction using COL7A1-carrying vectors. Furthermore, 
two recent reports indicate that application of MSCs 
improves wound healing [21] and transplantation effi-
ciency [22] in patients with EB. However, recent reports 
demonstrate that ASCs, MSCs derived from adipose tis-
sue, can also be trans-differentiated into keratinocyte-like 
cells just by co-incubation with conditioned medium or 
cultured keratinocytes. Furthermore, those cells were able 
to form a stratified structure similar to human skin on 
top of a decellularized dermal matrix [12]. Paunescu et al. 
demonstrated the differentiation of bone-marrow derived 
mesenchymal stem cells into keratinocytes by incubation 
with a mixture of different growth factors [13].
We therefore hypothesize that also USCs have the 
potential to trans-differentiate into keratinocyte-like 
cells, which could later be used for the engineering of 
transplantable skin-grafts by gene-therapy as therapeutic 
approach for patients with EB. The isolation of functional 
USCs from patients with EB, as shown here, is the first 
important step in this process.
Next, a reproducible protocol for the generation of 
therapeutically relevant amounts of keratinocytes from 
USCs is required, which might be hindered by their lim-
ited number, proliferation and differentiation potential. 
However, we are convinced to circumvent this problem 
by generating purer USCs-populations by flow cytometry 
or other enrichment strategies in the future. Further-
more, since USCs can be easily, inexpensively and pain-
lessly isolated, the limited number of cells can be to some 
degree compensated by processing multiple samples.
Conclusions
Summarized, the work presented here suggests a prom-
ising novel non-invasive route for obtaining stem cells 
from patients with EB, which might be used for thera-
peutic approaches after resolving the last open techni-
cal issues. Importantly, the retrieval of USCs might also 
be beneficial for the treatment of autoimmune disorders 
[23] and other diseases, where taking biopsies is painful.
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